Navigation Links
Repligen Announces Conference Call of Fourth Quarter and Fiscal Year 2010 Financial Results
Date:6/2/2010

 In addition, we are the world's leading supplier of recombinant Protein A, the sales of which partially fund the advancement of our development pipeline while supporting our financial stability.  Repligen's corporate headquarters are located at 41 Seyon Street, Building #1, Suite 100, Waltham, MA 02453.  Additional information may be requested from www.repligen.com.

This press release contains forward-looking statements which are made pursuant to the safe harbor provisions of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. The forward-looking statements in this release do not constitute guarantees of future performance. Investors are cautioned that statements in this press release which are not strictly historical statements, including, without limitation, statements regarding current or future financial performance and position, management's strategy, plans and objectives for future operations, plans and objectives for product development, plans and objectives for present and future clinical trials and results of such trials, plans and objectives for regulatory approval, litigation, intellectual property, product development, manufacturing plans and performance such as the anticipated growth in the monoclonal antibody market and our other target markets and projected growth in product sales, constitute forward-looking statements. Such forward-looking statements are subject to a number of risks and uncertainties that could cause actual results to differ materially from those anticipated, including, without limitation, risks associated with: the success of current and future collaborative relationshi
'/>"/>

SOURCE Repligen Corporation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Repligen Announces Conference Call of Third Quarter Fiscal Year 2008 Results
2. Repligen Announces Settlement with Bristol-Myers Squibb in Orencia(R) Lawsuit
3. Repligen Reports Fourth Quarter and Fiscal Year 2008 Financial Results
4. Repligen Announces Conference Call of First Quarter Fiscal Year 2009 Results
5. Repligen Receives Research Grants to Support Friedreichs Ataxia Development Program
6. Repligen Announces Publication of Positive Results with Proprietary HDAC Inhibitor in Huntingtons Disease Model
7. Repligen to Present at the 2008 UBS Global Life Sciences Conference Wednesday, September 24th, 1:00 p.m. EDT
8. Repligen to Present at the Rodman & Renshaw 10th Annual Healthcare Conference Monday, November 10th, 4:55 p.m. EST
9. Repligen Announces Conference Call of Third Quarter Fiscal Year 2009 Results
10. Repligen to Present at the BIO CEO & Investor Conference Monday, February 9th, 11:30 a.m. EST
11. Repligen Reports Third Quarter Fiscal Year 2009 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/22/2014)...   , ... zu KLOX    Mariano ... Officer bestellt    KLOX ist bestens ... zugelassenen Behandlungssystems zur Wundheilung zu beginnen    , ... sehr erfreut, die folgenden personellen Veränderungen anzukündigen: ...
(Date:11/21/2014)... , Nov. 21, 2014   TRU-D SmartUVC LLC ... their superbug-killing UVC automated disinfection robot, TRU-D SmartUVC, at FIS ... from Nov. 23 to 26 at Stand 23. ... United Kingdom,s largest infection-related event of ... societies to one of the leading events of its type ...
(Date:11/21/2014)... Offering a complete line of laboratory ... promotion . The Sartorius Entris Balance is the perfect ... and easy-to-maintain balance entry level balance. , The Entris ... to help customer’s bridge the gap between a basic ... very durable. Sartorius is the second biggest balance manufacturer ...
(Date:11/21/2014)... Palo Alto, Calif. (PRWEB) November 20, 2014 ... (CHI), a nonprofit, public policy research organization representing ... and pharmaceutical firms, and PwC US ... other states in life sciences industry growth. The ... and 2013. The 2015 California Biomedical Industry ...
Breaking Biology Technology:KLOX Technologies meldet Neubesetzung von Führungspositionen 2KLOX Technologies meldet Neubesetzung von Führungspositionen 3KLOX Technologies meldet Neubesetzung von Führungspositionen 4KLOX Technologies meldet Neubesetzung von Führungspositionen 5TRU-D SmartUVC to Showcase Superbug-Killing Robot at FIS 2014 2TRU-D SmartUVC to Showcase Superbug-Killing Robot at FIS 2014 3Pipette.com Announces an Extension on the Sartorius Entris Balance Promotion to the End of 2014 2California Healthcare Institute and PwC Report Boom in California’s Biomedical Industry 2California Healthcare Institute and PwC Report Boom in California’s Biomedical Industry 3California Healthcare Institute and PwC Report Boom in California’s Biomedical Industry 4
(Date:11/6/2014)... 2014 - Insilico Medicine, Inc, a Baltimore-based bioinformatics ... related diseases announced a research collaboration with the ... Oncology, Inc (OTC: CSBR). , "There are many ... but Champions Oncology,s TumorGraft technology is unique in ... regimen experimentally generating vast amounts of valuable data. ...
(Date:11/5/2014)... de Janeiro, Brazil -Individuals show great diversity in their ... males and females greatly differ in their perceptual evaluation ... of smell tests. , Sex differences in ... behaviors and may be connected to one,s perception of ... emotions. Thus, women,s olfactory superiority has been suggested to ...
(Date:11/4/2014)... Medicine announced today that it is a Grand ... Bill & Melinda Gates Foundation. Laura Goetzl, ... Sciences; and Vice Chair of Research and Academic ... pursue an innovative global health and development research ... Neurodevelopment.", Grand Challenges Explorations (GCE) funds individuals worldwide ...
Breaking Biology News(10 mins):Insilico Medicine, Inc announces research collaboration with Champions Oncology, Inc 2The female nose always knows: Do women have more olfactory neurons? 2Temple University School of Medicine receives Grand Challenges Explorations grant 2
... that can break down plant biomass into the precursors of ... to produce alternatives to petroleum. But the potential of this ... cannot break down lignin, a highly stable polymer that makes ... Streptomyces bacteria are among few microorganisms known to ...
... 14, 2013As scientists continue to unravel the complexity of the ... role in both normal physiology and disease, one particular class ... attention. Guest Editor Tom Cech, PhD and Executive Editor Fintan ... advancing research area in their Editorial " The (Noncoding) ...
... Studies at Le Bonheur Children,s Hospital in Memphis, ... RSV, replicate in humans, mutate to avoid the immune ... DeVincenzo, MD, medical director of Molecular Diagnostics and Virology ... Microbiology, Immunology, and Molecular Biology at The University of ...
Cached Biology News:A microbial biorefinery provides new insight into how bacteria regulate genes 2A microbial biorefinery provides new insight into how bacteria regulate genes 3Noncoding RNAs offer huge therapeutic and diagnostic potential 2Leading RSV researcher publishes work at Le Bonheur Children's 2Leading RSV researcher publishes work at Le Bonheur Children's 3
... 220 V, is used for agitation and mixing ... staining and destaining of gels and blots, and ... (8-40 rpm) and can handle a maximum load ... two 29 x 21 cm platforms covered with ...
...
...
... Wyatt Technology's family of light scattering instruments. ... temperature chromatograph and enables you to get ... The HTmD is easily installed in the ... Alliance 2000 device and enables you to ...
Biology Products: